BiOptic Inc.
BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications. It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits. BiOptic Inc.was fou… Read more
BiOptic Inc. (6850) - Net Assets
Latest net assets as of June 2025: NT$454.55 Million TWD
Based on the latest financial reports, BiOptic Inc. (6850) has net assets worth NT$454.55 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$586.19 Million) and total liabilities (NT$131.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$454.55 Million |
| % of Total Assets | 77.54% |
| Annual Growth Rate | 26.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 43.3 |
BiOptic Inc. - Net Assets Trend (2020–2024)
This chart illustrates how BiOptic Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BiOptic Inc. (2020–2024)
The table below shows the annual net assets of BiOptic Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$461.75 Million | +4.18% |
| 2023-12-31 | NT$443.21 Million | +3.71% |
| 2022-12-31 | NT$427.36 Million | +14.03% |
| 2021-12-31 | NT$374.79 Million | +106.84% |
| 2020-12-31 | NT$181.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BiOptic Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8022900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$56.07 Million | 12.47% |
| Common Stock | NT$300.81 Million | 66.89% |
| Other Components | NT$92.84 Million | 20.64% |
| Total Equity | NT$449.72 Million | 100.00% |
BiOptic Inc. Competitors by Market Cap
The table below lists competitors of BiOptic Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
United Bank Ltd
KAR:UBL
|
$12.61K |
|
BIOTIME
BE:BT3
|
$12.61K |
|
Ceylon Grain Elevators PLC
CM:GRANN0000
|
$12.61K |
|
King House CO., Ltd.
TWO:4419
|
$12.61K |
|
ScripsAmerica Inc
PINK:SCRCQ
|
$12.60K |
|
Waste Plastic Upcycling AS
OL:WPU
|
$12.59K |
|
Gemfields Plc
LSE:GEM
|
$12.59K |
|
Danang Airport Services JSC
VN:MAS
|
$12.58K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BiOptic Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 431,774,000 to 449,721,000, a change of 17,947,000 (4.2%).
- Net income of 22,727,000 contributed positively to equity growth.
- Dividend payments of 5,324,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$22.73 Million | +5.05% |
| Dividends Paid | NT$5.32 Million | -1.18% |
| Other Changes | NT$544.00K | +0.12% |
| Total Change | NT$- | 4.16% |
Book Value vs Market Value Analysis
This analysis compares BiOptic Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.87x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.74x to 2.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$9.04 | NT$42.85 | x |
| 2021-12-31 | NT$14.60 | NT$42.85 | x |
| 2022-12-31 | NT$13.83 | NT$42.85 | x |
| 2023-12-31 | NT$14.30 | NT$42.85 | x |
| 2024-12-31 | NT$14.91 | NT$42.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BiOptic Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.05%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.21%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.33x
- Recent ROE (5.05%) is below the historical average (11.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 14.40% | 20.98% | 0.43x | 1.62x | NT$7.92 Million |
| 2021 | 12.57% | 25.80% | 0.43x | 1.14x | NT$9.44 Million |
| 2022 | 14.64% | 26.48% | 0.44x | 1.25x | NT$19.42 Million |
| 2023 | 8.74% | 16.54% | 0.37x | 1.42x | NT$-5.43 Million |
| 2024 | 5.05% | 11.21% | 0.34x | 1.33x | NT$-22.25 Million |
Industry Comparison
This section compares BiOptic Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BiOptic Inc. (6850) | NT$454.55 Million | 14.40% | 0.29x | $12.60K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |